Contactless health monitoring technology developer Xandar Kardian announced today that it closed a $10 million Series A financing round.
Toronto-based Xandar Kardian’s Series A round was led by Phoenix Venture Partners, Portfolia Active Aging & Longevity Fund and Taronga Ventures, among others, according to a news release.
Xandar Kardian develops the XK300 autonomous health monitoring solution, which it touts as the world’s first and only commercially available, contact-free, continuous vital sign monitoring system with FDA 510(k) clearance as a Class II medical device.
The contactless solution for vital sign monitoring offers accurate measurements that can be leveraged to predict health outcomes for better proactivity by providers, the company said. Its radar technology can smart-build implementation to provide commercial and public building operators with real-time occupancy measurements for effective energy optimization.
Xandar Kardian’s XK300 system received FDA 510(k) clearance in April of this year and currently has 32 patents granted and 11 patents pending.
“At Xandar Kardian, our goal is to enable predictive and preventive care for people everywhere by leveraging the advanced technologies available today. Our radar-based solutions are the future of healthcare and patient monitoring, allowing providers to take continuous vital sign measurements without any intervention – a true breakthrough that will save lives,” Xandar Kardian Founder & CEO Sam Yang said in the release. “The funds raised in this financing round will support the commercial rollout of our healthcare solutions and the expansion of our RealTech business in a digital-first era.”